"Pharmaceutical Express" 8 non-conforming drugs to stop selling Jia and bio-Hong Kong Stock Exchange main board listing plan.

September 23, 2020 / Medical Information At a Glance: Blueprint Precision KIT Inhibitor Key Clinical Trial Results Are Positive; Sansheng National Health Anti-IL-4R Alpha Monoantiba Clinical Trial Approved by NMPA; 28 Drug Approval Documents for Tigrillo Tablets, Injection OmmaJu Monoantigen, etc.; First Idala Injection for ALS Listing in China... Daily fresh medicine news, speed reading society and you pay attention to! Part 1 Policy Brief The State Council issued a document to vigorously promote Internet medical care, Online drug sales, prescription outflow 21, the General Office of the State Council issued "on the new business model to lead the accelerated development of new consumption views." the
comments mentioned actively carrying out artificial intelligence applications in the field of consumer services, enriching 5G technology applications, accelerating the development of wearable devices, mobile smart terminals, smart homes, ultra-high definition and high-tech video terminals, intelligent teaching assistants, intelligent academic partners, medical electronics, medical robots and other intelligent products, and enhancing the support of new consumer technologies.
, we will actively develop Internet health care services, and vigorously promote time-by-time appointments, Internet consultations, electronic prescriptions, drug network sales and other services.
(Sina Pharmaceutical News) CDE issued the "Drug Clinical Trial Data Monitoring Committee Guidelines (Trial)" circular to guide the bidders to establish a drug clinical trial data monitoring committee, regulate the monitoring activities of the data monitoring committee, promote the protection of the rights and interests of subjects and clinical trial reliability, CDE developed the "Drug Clinical Trial Data Monitoring Committee Guidelines (Trial)."
approved by the State Drug Administration, is heeded and shall be implemented from the date of publication.
(CDE) 8 non-conforming drugs suspended sale, recall september 21, Heilongjiang Provincial Drug Administration issued a drug quality sampling announcement.
According to the announcement, the sampling found 8 batches of non-compliant drugs, of which 7 are Chinese medicine tablets: hot licorice, hot mutton (drink tablets), golden cherry blossoms, vinegar cream, fried pecans, hemp nuts, hawthorn;
(Heilongjiang Provincial Drug Administration) Part 2 After observation Jia and Bio announced the listing plan of the main board of the Hong Kong Stock Exchange Jia and Bio announced the listing plan of the main board of the Hong Kong Stock Exchange.
expects to sell 119,881,000 shares worldwide, of which about 107,892,000 will be sold internationally and the remaining 11,989,000 will be sold in Hong Kong at a price of HK$20.30 to HK$24.00 per share.
company will go on sale in Hong Kong from 9 am on the 23rd until 12 noon on the 28th.
shares, codenta as 6998, are expected to begin trading on the Hong Kong Stock Exchange on October 7.
Siemens and Novartis have announced a partnership to design, develop and commercialize diagnostic tests for Novartis' therapeutic product line, just days after the company and Novartis teamed up to develop blood tests for multiple sclerosis.
project of this collaboration is the immunometric determination of serum neural silk light chains in patients with multiple sclerosis and other neurological disorders.
the treatment sector is expected to expand to $23.5 billion by 2025.
(Sina Pharmaceutical News) Shufang Pharmaceuticals and Minoryx reached an agreement on the innovative rare disease drug Leriglitazone and Minoryx announced an exclusive licensing agreement for the innovative rare disease drug Leriglitazone.
Under the terms of the agreement, Shufang Pharmaceuticals will receive exclusive development and commercialization interests for Leriglitazone's treatment of X-chain adrenal white blood malnutrition in Chinese mainland, Hong Kong and the Macao Special Administrative Region, and Minoryx will receive a down payment of up to $78 million and a milestone payment, as well as a double-digit annual net sales share.
(AP) - The key clinical trial results of the Part 3 Drug News Blueprint Precision KIT Inhibitor positive Blueprint announced that its precision therapy Ayvakit obtained positive top-line results in Phase 1 clinical trials exPLORER and Phase 2 clinical trials pathFINDER in patients with advanced systemic hypertrophic hypertrophic disease.
data showed that Ayvakit significantly reduced the load on hypertrophoblastic cells, patients showed high total and total remission rates, and sustained clinical benefits.
(Pharmaceutical Mingkangde) O-drug, chemotherapy, and beva single-anti-four-line treatment of advanced non-scale NSCLC research recently, ESMO Conference announced a focus on combined immunotherapy randomized PHASE III. phase trial data.
results showed that navuliyu monoantigen (O-drug) combined with carbalin, yew alcohol and beva bead monotherapy advanced or relapsed non-scaly NSCLC significantly extended PFS compared to the placebo group, reducing the risk of disease progression by 44%.
Navuliyu monoantitor and beva bead monoantitor and chemotherapy combination drug has a strong scientific basis, cytotoxic chemotherapy can stimulate anti-tumor immune response by releasing immunogenic tumor antigens, and bevajuda monoantimmune in addition to anti-angiogenesis, but also can regulate the immune microenvironment, promote T-cell tumor immersion, thereby enhancing the PD-1 monoantimmune recovery body's ability to fight cancer immunity.
(Pharmaceutical Rubik's Cube) PACIFIC Study OS Results Re-renewed PACIFIC Study (designed to assess durvalumab's efficacy in patients with local advanced non-small cell lung cancer who did not progress after synchronous chemotherapy with platinum-containing programs) was published in the European Esteology Conference OS data and 4-year survival data show that Durvalumab consolidates the treatment of nearly 4 years of medium OS and 50% of the 4-year survival rate, solidified its status as an inseficiable phase III. Phase III NSCLC patients after simultaneous chemotherapy immunodation therapy standard therapeutic position.
(CPhI Pharmaceuticals Online) Kangzhe Pharmaceuticals /Sun Pharmaceuticals Tyraju Monoantitor Phase III Clinical 21st, Kangzhe Pharmaceuticals/Sun Pharmaceuticals Tiraju Monoantitor Treatment of Moderate to Severe Plaque Psoriasis Phase III Clinical First Publicity.
Tyraju monoantigen is a humanized IgG1/k monoclonal antibody that selectively, highly affinity-binding to p19 sub-base of leukocyte mesokine 23 (IL-23) inhibits its interaction with IL-23 receptors, thereby inhibiting the release of inflammatory cytokines and coercion factors for the treatment of psoriasis.
(Insight Database) Kangfang BioPD-1/VEGF dual anti-AK112 initiated clinical 21st, Kangfang Bio started AK112 treatment of advanced solid tumor phase I/II clinical.
AK112 is Kangfang's second clinical dual-anti-product, targeting PD-1/VEGF.
AK112 is a dual anti-new drug developed by Kangfang Bio.
the target VEGF and PD-1, respectively, as regulatory factors and immune checkpoints for angiogenesics, which play an important role in tumor angiogenesic and immune escape.
(Insight Database) BMS/Bluebird Bio multiple myeloma CAR-T therapy "World War II" was reviewed by the FDA on the 22nd, BMS and Bluebird Bio announced that the FDA has accepted and granted its biological products license application (2 BLA) priority review for the study of B-cell mature antigen-oriented chimic antigen-directed inlay antigen recipient (CAR) T-cell immunotherapy idecabtagene vice cel (ide cel) for the treatment of adult multiple myeloma patients who have received at least three treatments.
the FDA refused to review the BLA first submitted by the two drug companies in March.
(Sina Pharmaceutical News) Sansheng Guojian anti-IL-4R alpha monoantigen clinical trial was approved by NMPA Sansheng Pharmaceuticals announced that its Sansheng Guojian independently developed anti-white melebinin 4 subject alpha (IL-4R alpha) humanized monoclonal antibody drug recently obtained NMPA approval to carry out clinical trials of adult moderate to severe dermatitis patients requiring systematic treatment.
addition, the product in the United States clinical Phase I trial recently completed the first subjects into the group.
(Agency) Beda Pharmaceuticals Ectinib New Adaptive Diseases Reported for postoperative assisted treatment 22, Beda Pharmaceuticals issued a notice that the company declared the third application for the listing of hydrochloric acid Ectinib was accepted by NMPA, adaptation as postoperative assisted treatment.
Currently, Ectini has been approved for two adaptations: (1) single drug for the treatment of patients with local late stage or metastasis non-small cell lung cancer with sensitive mutations in the skin growth factor gene;
(Beda Pharmaceuticals Announcement) Colum medium long-chain fat milk / amino acids (16) / glucose (30%) injection first imitation listed on the 22nd, Colum Pharmaceuticals 3 classes of generic drugs medium long-chain fat milk / amino acids (16) / glucose (30%) injection market application was accepted by CDE, the first domestic market.
is a three-cavity bag product that benefits from Colum's injections and is intended for patients who need extraintestinal nutritional support.
(Insight database) for Grelo tablets, injection of omaju monoantigen and other 28 drug approval documents to be received NMPA issued drug approval documents to be received information, including the first three total Lozolofen sodium tablets, stone drug Oitigrello tablets, Beijing Novartic Pharmaceutical injection with omaju monoanti, double crane pharmaceutical glucose injection, Lilly lactose peptide injection and other 28 drugs.
(NMPA) the country's first Idalaphon injection for ALS-listed NMPA has approved the first sound Dongyuan pharmaceutical Ida Raven injection (including 5 ml: 10mg, 20ml: 30mg two specifications) new adaptive disorders for the treatment of freezing human disease (ALS).
is the world's second and first domestic-listed Idalaven injection, which is expected to help freeze patients live longer and improve their quality of life.
(NMPA) is being approved recently, NMPA shows that the positive day of the Kagle net film 4 imitation listing applications into the "in the approval" state.
The drug reduces the level of glucose in the blood by inhibiting the re-absorption of glucose by the renal tube, thus achieving the effect of treating type 2 diabetes, and the drug has therapeutic effect on type 2 diabetes at all stages because it does not rely on insulin secretion and action levels.
(NMPA) Heathcote Pypsy statin tablets will soon be approved, NMPA official website data show that Hesco's Pescopristamin tablets 4 imitation listing applications into the "in the approval" stage, is expected to usher in good news in the near future.
pyridine tablets as a drug for the renin-angiotensin system, and the adaptation is hypertension and congesitive heart failure.
(NMPA) Deqi Pharma Class 1 new drugs in China declared clinical acceptance 22, CDE publicity, Deqi Pharmaceuticals Class 1 new drug ATG-016 clinical trial applications were accepted.
this is a second-generation SINE compound with a larger treatment window, this is the first time ATG-016 declared clinical in China, the proposed development of indications for high-risk bone marrow growth abnormal syndrome.
(CDE) Beda Pharmaceuticals Ectinib New Adaptation Report listed for postoperative assisted treatment 22, Beda Pharmaceuticals issued a notice that the company declared the third application for the listing of hydrochloric acid Ectinib was accepted by NMPA, adaptation as postoperative assisted treatment.
Currently, Ectini has been approved for two adaptations: (1) single drug for the treatment of patients with local late stage or metastasis non-small cell lung cancer with sensitive mutations in the skin growth factor gene;
(Beda Pharmaceuticals Announcement) Zhifei Biorotylating Virus Inactivated Vaccines Obtaining Clinical Trial Approval Notice Zhifei Biologicals announced that the wholly-owned subsidiary Zhifei Green Bamboo Rotavirus Inactivated Vaccines obtained the Approval Notice of the National Drug Administration's Drug Clinical Trials and agreed to conduct clinical trials of this product, and its clinical trial application was accepted on June 24, 2020.
will carry out the relevant clinical trial work as soon as possible in accordance with the requirements of the clinical trial approval notice.
(Zhifei Biological Announcement) Da'an gene new coronavirus detection products by the medical device registration certificate Daan gene announced that recently, the company's new coronavirus 2019-nCoV nucleic acid testing kit (fluorescent PCR method) obtained the National Drug Administration issued a medical device registration certificate.
valid from the date of ratification until 20 September 2021.
(Da'an Gene Announcement) Jiangsu Wu Zhong injection with Esomerazole sodium drug registration certificate Jiangsu Wu Zhong issued a notice that recently, the company's subsidiary Suzhou Pharmaceutical Factory received the Approval of the State Drug Administration issued the injection of Esomerazole sodium "drug registration certificate."
protonization under acidic conditions, Esomeprazole is transformed into a compound with inhibitory H/K-ATP enzyme activity, subsulfuramide, quickly combined with the -base binding of cysteine on the H/K-ATP enzyme to form a disulfur bond, thereby inflamed enzymes, specific to inhibit the activity of the stomach wall cells in H/K-ATP enzyme to inhibit gastric acid secretion.
(Jiangsu Wu Zhong Announcement)